A COST VARIATION ANALYSIS OF DRUGS PRE-SCRIBED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Yash Panchal; Bhavesh Vyas

doi:10.55489/njmr.13012023917

Authors

Yash Panchal Narendra Modi Medical College, Maninagar, Ahmedabad, India
Bhavesh Vyas Narendra Modi Medical College, Maninagar, Ahmedabad, India

DOI:

https://doi.org/10.55489/njmr.13012023917

Keywords:

Rheumatoid arthritis, DMARDs, Cost of illness

Abstract

Background: The rheumatologists have several drugs to choose from, either alone or in combination; each with different costs, monitoring protocols, and potential risks and benefits. Pharmacoeconomic analysis results help rheumatologists choose drugs for their patients.

Objective: Objective of this prospective observational study was to perform a cost-variation analysis of drugs prescribed for the treatment of rheumatoid arthritis (RA) in a Western-Indian tertiary care teaching hospital.

Materials and Methods: This prospective observational study was conducted in the rheumatology department of the study site. Study population included patients of both gender male and female, diagnosed with rheumatoid arthritis and on treatment. Prices of the drugs prescribed to the patients were obtained from different offline and online sources. The lowest and highest cost of brands in rupees (INR) for each drug, the cost ratio, percentage cost variation, and monthly cost for all the prescribed drugs were calculated.

Results: In our study, out of total 142 patients, 93 were females and 49 were males and the mean age was 49.11±15.89 years. The majority of patients were prescribed with Disease-modifying antirheumatic drugs (DMARDs). Frequently used non-steroidal anti-inflammatory drug (NSAID) was Diclofenac (n=48). A maximum cost ratio (15.6) was observed with prednisolone 5 mg TDS. The costliest and cheapest brand of prednisolone 5 mg TDS accounted for the maximum cost variability (1460%). Mean monthly cost varied among different drug classes.

Conclusion: Average cost of illness of patient with RA was estimated to be in the range of 2406/month to 2858/month in the year 2021.

References

Butola LK, Anjanker A, Vagga A, Kaple MN. Endogenous fac-tor and pathophysiology of rheumatoid arthritis: an autoim-mune disease from decades. Int J Cur Res Rev. 2020 Nov;12(22):34-40. Doi: https://doi.org/10.31782/IJCRR.2020.122216

Mititelu RR, Pădureanu R, Băcănoiu M, Pădureanu V, Docea AO, Calina D, Barbulescu AL, Buga AM. Inflammatory and oxidative stress markers-mirror tools in rheumatoid arthritis. Biomedicines. 2020 May 15;8(5):125. Doi: https://doi.org/10.3390/biomedicines8050125 PMid:32429264 PMCid:PMC7277871

Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatology international. 2021 May;41(5):863-77. Doi: https://doi.org/10.1007/s00296-020-04731-0 PMid:33175207

Silvagni E, Giollo A, Sakellariou G, Ughi N, D'Amico ME, Scirè CA, Huizinga TW. One year in review 2020: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2020 Mar 1;38(2):181-94. Doi: https://doi.org/10.55563/clinexprheumatol/n6zc67 PMid:32213264

Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and bio-logical therapies: a viewpoint in 2020. Annals of the rheumatic diseases. 2020 Dec 1;79(12):1532-43. Doi: https://doi.org/10.1136/annrheumdis-2020-217092 PMid:32963049

Sobue Y, Kojima T, Ito H, Nishida K, Matsushita I, Kaneko Y, Kishimoto M, Kohno M, Sugihara T, Seto Y, Tanaka E. Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis. Modern rheumatology. 2022 Jan;32(1):96-104. Doi: https://doi.org/10.1080/14397595.2021.1886653 PMid:33565350

Hsieh PH, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Annals of the rheumatic diseases. 2020 Jun 1;79(6):771-7. Doi: https://doi.org/10.1136/annrheumdis-2019-216243 PMid:32245893

Strand V, Shah R, Atzinger C, Zhou J, Clewell J, Ganguli A, Tundia N. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data. Current Medical Research and Opinion. 2020 Jan 2;36(1):161-8. Doi: https://doi.org/10.1080/03007995.2019.1658974 PMid:31433680

Ding Q, Shiltz D, Hossami D, Konieczny AM. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States. Expert Review of Pharmacoeconomics & Outcomes Research. 2022 Sep 8:1-1. Doi: https://doi.org/10.1080/14737167.2022.2117690 PMid:36004551

Tian L, Xiong X, Guo Q, Chen Y, Wang L, Dong P, Ma A. Cost-effectiveness of tofacitinib for patients with moderate-to-severe rheumatoid arthritis in China. Pharmacoeconomics. 2020 Dec;38(12):1345-58. Doi: https://doi.org/10.1007/s40273-020-00961-z PMid:32929677

Xu C, Wang X, Mu R, Yang L, Zhang Y, Han S, Li X, Wang Y, Wang G, Zhu P, Jin H. Societal costs of rheumatoid arthritis in China: a hospital based cross‐sectional study. Arthritis care & research. 2020 Apr;66(4):523-31. Doi: https://doi.org/10.1002/acr.22160 PMid:24023001

Shini VK, Aboobacker S, Pahuja S, Revikumar KG, Bhasi R. Pharmacoeconomic study of DMARDs in the management of rheumatoid arthritis. Int J Pharm Sci Rev Res. 2021;5(3):148-54.

Tugwell P. Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology (Oxford, England). 2020 Jun 1;39:43-7. Doi: https://doi.org/10.1093/oxfordjournals.rheumatology.a031494 PMid:11001379

Agarwal V, Tiwari P. Treatment and monitoring costs in rheumatoid arthritis: Preliminary results from an Indian set-ting. Indian Journal of Pharmaceutical Sciences. 2007;69(2):226. Doi: https://doi.org/10.4103/0250-474X.33148

Alex V, Cheruvallikattil S, Abraham S, Varghese B. Cost of illness of rheumatoid arthritis in south India. World Journal of Pharmaceutical Research. 2015 Aug 26;4(11):1305-15.

Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology. 2020 Jan 1;39(1):28-33. Doi: https://doi.org/10.1093/rheumatology/39.1.28 PMid:10662870

Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Annals of the rheumatic diseases. 2020 Sep 1;61(9):818-21. Doi: https://doi.org/10.1136/ard.61.9.818 PMid:12176807 PMCid:PMC1754210

Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, Momohara S, Hara M, Singh G, Yamanaka H. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Modern rheumatology. 2020 Feb 1;20(1):46-53. Doi: https://doi.org/10.3109/s10165-009-0236-3 PMid:19821162

Michauad K, Messe J, Choi HK, Wolfe F. Direct medical cost and their predictors in patients with rheumatoid arthritis. Arthritis & Rheumatism. 2022;48(10):2750-62. Doi: https://doi.org/10.1002/art.11439 PMid:14558079

Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Porter D, Kincaid W. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. The Lancet. 2020 Jul 17;364(9430):263-9. Doi: https://doi.org/10.1016/S0140-6736(04)16676-2 PMid:15262104